Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.59 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.59 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.59 |
| ▸ | BRD4 | O60885 | 1/20 | 0.58 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.58 |
| ▸ | P2RX7 | Q99572 | 4/20 | 0.55 |
| ▸ | MET | P08581 | 5/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | GALR3 | O60755 | 1/20 | 0.47 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17877382 | 0.91 | BRD4 (0.60) | TAS1R3TAS1R1TAS1R2BRD4CREBBP | |
| SCHEMBL17877277 | 0.90 | P2RX7 (0.59) | TAS1R3TAS1R1TAS1R2BRD4CREBBP | |
| SCHEMBL17877302 | 0.83 | TRPV1 (0.57) | TAS1R3TAS1R1TAS1R2BRD4CREBBP | |
| SCHEMBL17868232 | 0.81 | BRD4 (0.66) | BRD4CREBBPP2RX7METMAPK1 | |
| SCHEMBL17877381 | 0.81 | BRD4 (0.60) | TAS1R3TAS1R1TAS1R2BRD4CREBBP | |
| SCHEMBL17877281 | 0.81 | CREBBP (0.55) | TAS1R3TAS1R1TAS1R2BRD4CREBBP | |
| SCHEMBL17877212 | 0.80 | NPC1 (0.57) | BRD4CREBBPP2RX7METMAPK1 | |
| SCHEMBL17868294 | 0.80 | BRD4 (0.71) | BRD4CREBBPP2RX7MAPK1 | |
| SCHEMBL17877307 | 0.80 | CREBBP (0.54) | BRD4CREBBPP2RX7MAPK1 | |
| SCHEMBL17877294 | 0.79 | CREBBP (0.53) | TAS1R3TAS1R1TAS1R2BRD4CREBBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200181142-A1 | Derivatives And Methods Of Treating Hepatitis B Infections | NOVIRA THERAPEUTICS INC (US) | 2020-06-11 | — | — | US | disclosed |
| US-20190031653-A1 | Derivatives And Methods Of Treating Hepatitis B Infections | NOVIRA THERAPEUTICS, INC. | 2019-01-31 | — | — | US | disclosed |
| US-20170158691-A1 | Derivatives And Methods Of Treating Hepatitis B Infections | NOVIRA THERAPEUTICS, INC. | 2017-06-08 | — | — | US | disclosed |
| US-20170158691-A1 | Derivatives And Methods Of Treating Hepatitis B Infections | NOVIRA THERAPEUTICS, INC. | 2017-06-08 | — | — | US | disclosed |
| US-9550779-B2 | Derivatives and methods of treating hepatitis B infections | NOVIRA THERAPEUTICS, INC. (US) | 2017-01-24 | — | — | US | disclosed |
| US-9550779-B2 | Derivatives and methods of treating hepatitis B infections | NOVIRA THERAPEUTICS, INC. (US) | 2017-01-24 | — | — | US | disclosed |
| US-20160185779-A1 | DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | NOVIRA THERAPEUTICS, INC. | 2016-06-30 | — | — | US | disclosed |
| US-20160185779-A1 | DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | NOVIRA THERAPEUTICS, INC. | 2016-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190031653-A1 | Derivatives And Methods Of Treating Hepatitis B Infections | HAVCR2, PYGL, HCCS | TAS1R3 4702/4885TAS1R1 4761/4885TAS1R2 4770/4885 |
| US-20200181142-A1 | Derivatives And Methods Of Treating Hepatitis B Infections | HAVCR2, PYGL, HCCS | TAS1R3 4702/4885TAS1R1 4761/4885TAS1R2 4770/4885 |
| US-20170158691-A1 | Derivatives And Methods Of Treating Hepatitis B Infections | HAVCR2, PYGL, HCCS | TAS1R3 4702/4885TAS1R1 4761/4885TAS1R2 4770/4885 |
| US-20160185779-A1 | DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | HAVCR2, PYGL, HCCS | TAS1R3 4702/4885TAS1R1 4761/4885TAS1R2 4770/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.